Bulk Pharmaceutical API Sources for ORSERDU

Bulk Pharmaceutical API Sources for ORSERDU

Vendor	Vendor Homepage	Vendor Sku	API Url
AbaChemScene		CS-6306
AbaChemScene		CS-6324
MedChemexpress MCE		HY-19822
MedChemexpress MCE		HY-19822A
DC Chemicals		DC10182

ORSERDU Bulk Active Pharmaceutical Ingredient (API) Sources

Last updated: February 19, 2026

This report analyzes the current landscape of bulk active pharmaceutical ingredient (API) sources for ORSERDU (elacestrant), a selective estrogen receptor degrader (SERD) approved for the treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations. The analysis focuses on identifying key manufacturers, their manufacturing capabilities, and potential supply chain risks.

Who Are the Primary Manufacturers of Elacestrant API?

The primary manufacturer of elacestrant API is Menarini Group, the originating pharmaceutical company for ORSERDU. Menarini Group's internal manufacturing capabilities or its contracted partners are responsible for the bulk API production. Specific third-party Contract Development and Manufacturing Organizations (CDMOs) involved in the API synthesis are not publicly disclosed. However, the supply chain for such specialized oncology drugs typically involves highly regulated and vetted CDMOs with expertise in complex small molecule synthesis and stringent quality control protocols.

What are the Key Manufacturing Capabilities Required for Elacestrant API?

The synthesis of elacestrant is a multi-step organic chemistry process. Key manufacturing capabilities required include:

• Advanced Organic Synthesis: Expertise in complex, multi-step synthetic routes is essential. Elacestrant's structure requires precise control over stereochemistry and functional group transformations.
• cGMP Compliance: Manufacturing must adhere to current Good Manufacturing Practices (cGMP) as mandated by regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes rigorous quality control, process validation, and documentation.
• Process Scale-Up: The ability to scale production from laboratory quantities to commercial volumes (kilograms to metric tons) while maintaining purity, yield, and consistency is critical.
• Analytical Method Development and Validation: Robust analytical methods are required to characterize the API, identify and quantify impurities, and ensure batch-to-batch consistency. This includes techniques such as High-Performance Liquid Chromatography (HPLC), Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR), and X-ray Powder Diffraction (XRPD).
• Impurity Profiling and Control: Identification, quantification, and control of process-related impurities and degradants are paramount for patient safety. The synthesis pathway must be designed to minimize the formation of genotoxic impurities.
• Crystallization and Polymorph Control: The final API often requires specific crystalline forms (polymorphs) that impact its physical properties, such as solubility, stability, and bioavailability. Controlled crystallization processes are necessary.
• Handling of Hazardous Reagents: Certain synthetic steps may involve hazardous reagents or intermediates requiring specialized handling procedures and containment.

What is the Regulatory Landscape for Elacestrant API Manufacturing?

Elacestrant API manufacturing is subject to strict regulatory oversight. Key aspects include:

• Drug Master Files (DMFs): Manufacturers of elacestrant API must submit a DMF to regulatory authorities (e.g., FDA, EMA). The DMF contains detailed information about the manufacturing process, facilities, quality control, and stability of the API. Pharmaceutical companies using the API reference this DMF in their drug product applications.
• ICH Guidelines: International Council for Harmonisation (ICH) guidelines, such as ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), Q3A/B/C/D (Impurities), and Q11 (Development and Manufacture of Drug Substances), provide a global framework for API development and manufacturing.
• Inspections and Audits: Regulatory agencies conduct routine inspections of API manufacturing facilities to ensure compliance with cGMP. Pharmaceutical companies also conduct their own audits of API suppliers to assess their quality systems and manufacturing capabilities.
• Quality Agreements: Pharmaceutical companies and their API suppliers enter into quality agreements that define responsibilities for quality control, change management, deviations, and audits.

Are There Geopolitical or Supply Chain Risks Associated with Elacestrant API Sourcing?

The supply chain for specialized oncology APIs, including elacestrant, can be subject to various risks:

• Geographic Concentration of Manufacturing: If a significant portion of API manufacturing is concentrated in a single region or country, geopolitical instability, trade disputes, or natural disasters in that region can disrupt supply. While Menarini Group is headquartered in Italy, the actual manufacturing sites, whether internal or contracted, could be located globally.
• Reliance on Key Starting Materials (KSMs) and Intermediates: The synthesis of elacestrant involves several chemical intermediates. Disruptions in the supply of any of these upstream materials, whether due to manufacturing issues, regulatory actions, or trade restrictions, can impact the availability of the final API.
• CDMO Capacity and Prioritization: If elacestrant API is manufactured by third-party CDMOs, these organizations often produce APIs for multiple pharmaceutical clients. Prioritization of production schedules by the CDMO based on other clients' needs or market demand can affect the supply availability for elacestrant.
• Intellectual Property and Exclusivity: As a patented drug, the manufacture of elacestrant API is controlled by Menarini Group or its licensed partners. The expiry of patents can lead to increased competition from generic API manufacturers, potentially altering the supply landscape, but this is a future consideration.
• Quality Control Failures: A single quality failure or recall at an API manufacturing site can lead to significant supply disruptions and require a lengthy process to qualify alternative suppliers.
• Regulatory Changes: Evolving regulatory requirements for API manufacturing, impurity control, or environmental standards can necessitate significant investment and process changes, potentially impacting supply continuity.

What are the Potential Alternative Sourcing Strategies?

Given the proprietary nature of elacestrant API, alternative sourcing strategies primarily focus on ensuring supply continuity from the authorized manufacturer(s) or their approved subcontractors.

• Dual Sourcing for Critical Intermediates: While the final API is likely single-sourced by Menarini, strategic evaluation of upstream KSMs and critical intermediates for potential dual sourcing from qualified suppliers can mitigate risks.
• Supplier Relationship Management: Maintaining a strong, transparent relationship with the primary API manufacturer and understanding their supply chain vulnerabilities is crucial. This includes regular communication, joint risk assessments, and proactive planning.
• Contingency Planning: Developing robust contingency plans to address potential supply disruptions, including identifying potential backup manufacturing sites or alternative logistics routes, is essential.
• Internal Manufacturing Assessment: For pharmaceutical companies developing similar molecules, assessing the feasibility and cost-effectiveness of developing in-house API manufacturing capabilities can provide long-term strategic control. However, for a commercialized drug like ORSERDU, this is less applicable unless Menarini were to divest or expand its manufacturing base.

What is the Typical Lead Time for API Production?

The lead time for bulk API production can vary significantly depending on several factors:

• Manufacturing Scale: Larger batch sizes generally require longer production campaigns.
• Process Complexity: Multi-step syntheses with challenging chemistry or purification steps increase lead times.
• Facility Utilization: The availability and scheduling of manufacturing equipment and personnel at the API production site.
• Raw Material Availability: Lead times for sourcing critical starting materials and reagents.
• Regulatory Approvals: Time required for process changes or validation batches if any are needed.

For a complex oncology API like elacestrant manufactured under strict cGMP, typical lead times from order placement to finished API delivery can range from 6 to 12 months. This includes process development, validation, scale-up, raw material procurement, manufacturing campaigns, quality control testing, and release.

Summary of Elacestrant API Supply

The bulk active pharmaceutical ingredient (API) for ORSERDU (elacestrant) is primarily manufactured by or for the originating pharmaceutical company, Menarini Group. The synthesis demands advanced organic chemistry expertise, strict cGMP compliance, and robust quality control systems. Regulatory bodies like the FDA and EMA oversee API production through Drug Master Files and facility inspections. Potential supply chain risks include geopolitical factors, reliance on upstream intermediates, and CDMO capacity. Strategies to mitigate these risks involve strong supplier relationships, contingency planning, and, where feasible, dual sourcing of critical raw materials. Typical lead times for elacestrant API production are estimated to be between 6 to 12 months due to its complexity and regulatory requirements.

Key Takeaways

• Menarini Group is the primary entity responsible for elacestrant API sourcing and manufacturing.
• Manufacturing requires advanced synthesis capabilities, rigorous cGMP adherence, and comprehensive analytical controls.
• Regulatory oversight is stringent, involving DMF submissions and facility inspections by agencies like the FDA and EMA.
• Supply chain risks are present, including geopolitical uncertainties and upstream material dependencies.
• Mitigation strategies focus on supplier relationship management, contingency planning, and a deep understanding of the manufacturing process.

Frequently Asked Questions

1. Is elacestrant API manufactured by multiple CDMOs? Publicly available information does not specify whether elacestrant API is manufactured by multiple CDMOs. Typically, pharmaceutical companies maintain close control over their patented API supply chains, often utilizing one or two primary manufacturing partners.

2. What are the primary starting materials for elacestrant synthesis? The specific proprietary starting materials and intermediates for elacestrant synthesis are not publicly disclosed due to intellectual property considerations.

3. How does elacestrant API differ from other SERD APIs in terms of manufacturing complexity? While all SERD APIs are complex small molecules requiring multi-step synthesis, the specific chemical structure of elacestrant dictates its unique synthetic route and associated challenges, including stereochemical control and impurity profiles.

4. What is the typical purity specification for elacestrant API? Typical purity specifications for pharmaceutical APIs, including elacestrant, are generally above 98.0%, with stringent limits on specific impurities, including residual solvents, heavy metals, and process-related impurities, as defined in the API’s specification sheet and regulatory filings.

5. What happens if there is a disruption in the elacestrant API supply chain? A disruption would necessitate the activation of contingency plans, which could include drawing down existing API inventory, expediting production campaigns, or, in severe cases, seeking emergency authorization for alternative supply routes or manufacturers if pre-qualified.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from [FDA website - specific URL would be for DMF information if available, but general reference suffices here] [2] European Medicines Agency. (n.d.). Active substance. Retrieved from [EMA website - specific URL for API information if available] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Guidelines. Retrieved from [ICH website]